Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Dosimetry, and Preliminary Efficacy of 3D1015 in mCRPC
NCT07537010Phase 1Recruiting
- Sponsor
- Chunjing Yu
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 3D1015 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Chunjing Yu. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events, Occurrence of Dose-Limiting Toxicities and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
3D1015
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07537010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537010.